Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity

NCT07590219 on ClinicalTrials.gov · last registry update 2026-05-15

A small phase 4 — 30 participants, against a typical 75. Due to report April 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Change in Body Mass Index (BMI). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 30 March 2024 — 2 years so far. liraglutide is already approved in the US for cardiovascular disease and obesity, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Sao Paulo General Hospital
Sponsor type: Other
Enrollment: 30
Started: 2024-03-30
Primary completion: 2027-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Body Mass Index (BMI)

Conditions studied

Severe Obesity · Cardiovascular Function · Liraglutide · Childhood Obesity · Echocardiography · Speckle Tracking

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.